首页> 外文期刊>BMC Medical Genetics >Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations
【24h】

Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations

机译:针对性的下一代测序揭示了先前未鉴定的TSC1和TSC2突变

获取原文
获取外文期刊封面目录资料

摘要

Background Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in TSC1 and TSC2. Conventional DNA diagnostic screens identify a TSC1 or TSC2 mutation in 75 - 90% of individuals categorised with definite TSC. The remaining individuals either have a mutation that is undetectable using conventional methods, or possibly a mutation in another as yet unidentified gene. Methods Here we apply a targeted Next Generation Sequencing (NGS) approach to screen the complete TSC1 and TSC2 genomic loci in 7 individuals fulfilling the clinical diagnostic criteria for definite TSC in whom no TSC1 or TSC2 mutations were identified using conventional screening methods. Results We identified and confirmed pathogenic mutations in 3 individuals. In the remaining individuals we identified variants of uncertain clinical significance. The identified variants included mosaic changes, changes located deep in intronic sequences and changes affecting promoter regions that would not have been identified using exon-only based analyses. Conclusions Targeted NGS of the TSC1 and TSC2 loci is a suitable method to increase the yield of mutations identified in the TSC patient population.
机译:背景结节性硬化症(TSC)是由TSC1和TSC2突变引起的常染色体显性遗传疾病。常规的DNA诊断筛查可在75-90%的具有明确TSC分类的个体中识别TSC1或TSC2突变。其余的个体具有使用常规方法无法检测到的突变,或者可能是另一个尚未鉴定的基因中的突变。方法在这里,我们采用靶向的下一代测序(NGS)方法来筛选7名满足常规TSC临床诊断标准的个体的完整TSC1和TSC2基因组位点,其中使用常规筛选方法未鉴定出TSC1或TSC2突变。结果我们鉴定并确认了3名个体的致病性突变。在其余的个体中,我们确定了具有不确定临床意义的变体。鉴定出的变体包括镶嵌变化,位于内含子序列深处的变化以及影响启动子区域的变化,而这些变化不会通过仅基于外显子的分析来鉴定。结论靶向TSC1和TSC2基因座的NGS是增加TSC患者群体中鉴定出的突变产量的合适方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号